Literature DB >> 15241660

Platinum complexes with imino ethers or cyclic ligands mimicking imino ethers: synthesis, in vitro antitumour activity, and DNA interaction properties.

Francesco P Intini1, Angelina Boccarelli, Valentina C Francia, Concetta Pacifico, Maria F Sivo, Giovanni Natile, Domenico Giordano, Pietro De Rinaldis, Mauro Coluccia.   

Abstract

Both trans- and cis-[PtCl(2)(NH(3))(L)] compounds have been synthesized, L representing either the imino ether HN=C(OMe)Me having a Z or E configuration at the C=N double bond, or the cyclic ligands N = C(OMe)CH2CH2CH2 and N = C(Me)OCH2CH2 (compounds 1-4 for trans geometry and 5-8 for cis geometry, respectively). The cyclic ligands mimic the imino ether ligands but, differently from imino ethers, cannot undergo change of configuration. In a panel of human tumor cells, trans compounds inhibit growth much more than transplatin. Moreover, compound 1 in most cases is less active than 2, and 1 and 2 are less active than 3 and 4, respectively. For cis compounds with imino ethers, the activity is reduced (5) or unaffected (6) with respect to cisplatin. Moreover, unlike trans compounds, substitution of cyclic ligands (7,8) for imino ethers (5,6) generally decreases the activity. This determines, for compounds with cyclic ligands, an unusual inversion of the cis geometry requirement for activity of platinum(II) species. Importantly,1-4 and 5-8 partially circumvent the multifocal cisplatin resistance of A2780cisR cells, and 1-4 also overcome resistance from reduced uptake of 41McisR cells. DNA interaction regioselectivity of 1-4 and 5-8 is not substantially modified with respect to transplatin and cisplatin. However, both imino ethers and cyclic ligands slow down the DNA interstrand cross-link reaction, ( E)-HN=C(OMe)Me and N = C(Me)OCH2CH2 decreasing also its extent. Therefore, DNA interaction of 1-4 and 5-8 appears to be characterized by persistent monoadducts (1-4), and by monoadducts and/or intrastrand cross-links structurally different from those of cisplatin (5-8). This study demonstrates that ligand configuration modulates the activity of both trans and cis compounds, and supports the development of platinum drugs based on their coordination chemistry to combat cisplatin resistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15241660     DOI: 10.1007/s00775-004-0572-x

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  22 in total

1.  In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands.

Authors:  M Coluccia; A Nassi; A Boccarelli; D Giordano; N Cardellicchio; D Locker; M Leng; M Sivo; F P Intini; G Natile
Journal:  J Inorg Biochem       Date:  1999-10       Impact factor: 4.155

Review 2.  Recognition of cisplatin adducts by cellular proteins.

Authors:  M Kartalou; J M Essigmann
Journal:  Mutat Res       Date:  2001-07-01       Impact factor: 2.433

3.  DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2].

Authors:  V Brabec; O Vrána; O Nováková; V Kleinwächter; F P Intini; M Coluccia; G Natile
Journal:  Nucleic Acids Res       Date:  1996-01-15       Impact factor: 16.971

4.  Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).

Authors:  J Holford; F Raynaud; B A Murrer; K Grimaldi; J A Hartley; M Abrams; L R Kelland
Journal:  Anticancer Drug Des       Date:  1998-01

5.  Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.

Authors:  L R Kelland; P Mistry; G Abel; S Y Loh; C F O'Neill; B A Murrer; K R Harrap
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

6.  Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues.

Authors:  N Farrell; Y Qu; L Feng; B Van Houten
Journal:  Biochemistry       Date:  1990-10-16       Impact factor: 3.162

7.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

Review 8.  DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair.

Authors:  Viktor Brabec
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2002

Review 9.  New metal complexes as potential therapeutics.

Authors:  Christiana Xin Zhang; Stephen J Lippard
Journal:  Curr Opin Chem Biol       Date:  2003-08       Impact factor: 8.822

10.  Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.

Authors:  C A Hills; L R Kelland; G Abel; J Siracky; A P Wilson; K R Harrap
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

View more
  8 in total

1.  Synthesis, structure and biological activity of a new and efficient Cd(II)-uracil derivative complex system for cleavage of DNA.

Authors:  Nuria A Illán-Cabeza; Rosario A Vilaplana; Ysmael Alvarez; Khalid Akdi; Sanae Kamah; Francisco Hueso-Ureña; Miguel Quirós; Francisco González-Vílchez; Miguel N Moreno-Carretero
Journal:  J Biol Inorg Chem       Date:  2005-11-03       Impact factor: 3.358

Review 2.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

3.  Synthesis, characterization, and biological activity of platinum II, III, and IV pivaloamidine complexes.

Authors:  Marilù Sinisi; Valentina Gandin; Teresa Saltarella; Francesco P Intini; Concetta Pacifico; Christine Marzano; Giovanni Natile
Journal:  J Biol Inorg Chem       Date:  2014-05-22       Impact factor: 3.358

Review 4.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

5.  Towards Antitumor Active trans-Platinum Compounds.

Authors:  Sheena M Aris; Nicholas P Farrell
Journal:  Eur J Inorg Chem       Date:  2009-04-01       Impact factor: 2.524

6.  Biophysical studies on the stability of DNA intrastrand cross-links of transplatin.

Authors:  Jana Kasparkova; Victoria Marini; Vendula Bursova; Viktor Brabec
Journal:  Biophys J       Date:  2008-08-01       Impact factor: 4.033

7.  Solution behaviour and biological activity of bisamidine complexes of platinum(II).

Authors:  C Marzano; S Mazzega Sbovata; F Bettio; R A Michelin; R Seraglia; T Kiss; A Venzo; R Bertani
Journal:  J Biol Inorg Chem       Date:  2007-01-09       Impact factor: 3.862

8.  Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts.

Authors:  Yao Zhao; Julie A Woods; Nicola J Farrer; Kim S Robinson; Jitka Pracharova; Jana Kasparkova; Olga Novakova; Huilin Li; Luca Salassa; Ana M Pizarro; Guy J Clarkson; Lijiang Song; Viktor Brabec; Peter J Sadler
Journal:  Chemistry       Date:  2013-06-03       Impact factor: 5.236

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.